InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$15.29−2.21 (-12.66%)
Close on Nov 18, 2026Market cap $83.97MP/E –Yield –
InMed Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
InMed Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2025 was $1.34M, down 21.7% year over year. For fiscal 2025 it was $1.71M, up 55.0% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.71M | +55.0% |
| FY2024 | Jun 30, 2024 | $1.10M | -21.5% |
| FY2023 | Jun 30, 2023 | $1.40M | +158.1% |
| FY2022 | Jun 30, 2022 | $543.55K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $184.19K | -60.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $403.16K | -18.3% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $576.65K | +23.7% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $175.63K | -39.3% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $460.89K | +42.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $493.41K | +2222.8% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $466.07K | -70.3% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $289.46K | +50.4% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $324.14K | +147.1% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $21.24K | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $1.57M | +528.9% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $192.51K | +5.6% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $131.16K | +17.6% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$491.02K | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $249.71K | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $182.28K | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $111.56K | – |
See a number that looks wrong?